Companies Dominating the Acute liver failure Market
- Ipsen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences, Inc.
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb
- AbbVie Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Zydus Pharmaceuticals Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of acute liver failure is estimated at USD 26.69 billion.
The acute liver failure market size was valued at USD 25.42 billion in 2024 and is set to exceed USD 53.56 billion by 2037, expanding at over 5.9% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of obesity, the increased geriatric population, and increased technological advancements in liver disease diagnosis will drive the market growth.
North America industry is anticipated to hold largest revenue share of 37% by 2037, due to rising alcohol consumption in the region.
The major players in the market are Ipsen, Gilead Sciences, Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Zydus Pharmaceuticals Inc. and others.
